Studies have revealed that the TGF-β signaling-upregulated noncoding RNA HDAC2-AS2 in HBV+HCC targets CDK9 in CD8+ T cells via exosomes, compromising their function and offering a novel therapeutic target for HBV-associated HCC[52]. Here, CDK9 is linked to hepatocellular carcinoma.